var data={"title":"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/contributors\" class=\"contributor contributor_credentials\">Clifford E Kashtan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/contributors\" class=\"contributor contributor_credentials\">Tej K Mattoo, MD, DCH, FRCP</a></dd><dd><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/contributors\" class=\"contributor contributor_credentials\">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/contributors\" class=\"contributor contributor_credentials\">Melanie S Kim, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alport syndrome (also referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/1-4\" class=\"abstract_t\">1-4</a>]. The prevalence of the disease is estimated at approximately 1 in 50,000 live births [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/5\" class=\"abstract_t\">5</a>]. Alport syndrome reportedly accounts for 0.3 to 2.3 percent of new cases of end-stage renal disease (ESRD) [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p>The pathogenesis, genetics, and renal pathology of Alport syndrome will be reviewed here. The clinical manifestations and course, diagnosis, and treatment of Alport syndrome are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Elucidation of the pathogenesis of Alport syndrome was facilitated by the chance observation that the glomerular basement membrane (GBM) of most affected patients did not bind antibodies from patients with anti-GBM antibody disease (including Goodpasture's syndrome) [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/3,8-10\" class=\"abstract_t\">3,8-10</a>]. This finding suggested an abnormality in type IV collagen, the protein target of anti-GBM antibodies. Subsequent research efforts confirmed that the primary abnormality resides in type IV collagen as discussed in the following section.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alport syndrome is a primary basement membrane disorder arising from mutations in genes encoding several members of the type IV collagen protein family.</p><p>Type IV collagen molecules are composed of three alpha chains that form triple-helical structures through specific interactions of C-terminal noncollagenous domains [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/9\" class=\"abstract_t\">9</a>]. Six distinct IV collagen chains are encoded by six different genes that are distributed in head-to-head pairs on three chromosomes. </p><p>The genes include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>COL4A1</em> and <em>COL4A2</em> at 13q34 </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>COL4A3</em> and <em>COL4A4</em> at 2q35-37</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>COL4A5</em> and <em>COL4A6</em> on chromosome X.</p><p/><p>The six alpha chains of type IV collagen form three triple helical protomers: alpha-1-1-2, alpha-3-4-5, and alpha-5-5-6. These protomers are further organized into collagen networks by end-to-end connections via C-terminal and N-terminal interactions.</p><p>Genetic analyses of affected families have identified the affected genes for the three different modes of transmission seen in patients with Alport syndrome: X-linked, autosomal recessive, and autosomal dominant &minus; as discussed in the following sections. These mutations disrupt the synthesis of type IV collagen <span class=\"nowrap\">and/or</span> the formation of type IV collagen protomers and networks. Based on pedigree studies, linkage analysis, and Sanger sequencing, the relative frequencies of the three genetic types were estimated at 80 percent for X-linked disease, 15 percent for autosomal recessive disease, and less than 5 percent for autosomal dominant disease. However, reports using next generation sequencing in Alport families suggest that autosomal dominant Alport syndrome may occur more frequently (20 to 30 percent of patients) than previously thought [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/11,12\" class=\"abstract_t\">11,12</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">X-linked inheritance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>X-linked Alport syndrome accounts for the majority of Alport syndrome cases. It arises from mutations in the <em>COL4A5</em> gene on the X chromosome, which codes for the alpha-5(IV) chain of type IV collagen [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/2,13-19\" class=\"abstract_t\">2,13-19</a>].</p><p>Confirmation of the direct pathogenetic role of these mutations was provided by an animal model in which a specific known human nonsense mutation was introduced into the mouse <em>COL4A5</em> gene [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/20\" class=\"abstract_t\">20</a>]. The primary clinical and pathologic findings of human X-linked disease were recapitulated in this animal model.</p><p>This mode of inheritance leads to important clinical characteristics in affected families:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Father to son transmission does not occur, since the father passes only the unaffected Y chromosome to his son.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Women with X-linked Alport syndrome are heterozygous for disease-causing mutations. Almost all heterozygotes have some degree of hematuria, and a significant minority develop renal failure [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/21\" class=\"abstract_t\">21</a>]. The variable course in women is probably due to lyonization, by which only one X chromosome is active per cell. As a result, in most women with X-linked Alport syndrome, roughly one-half of the cells will express the mutant X gene and the remaining cells the normal <em>COL4A5</em> gene, leading to a varied phenotype that is generally less severe than in affected males. The influence of X-inactivation on renal outcomes in heterozygotes was recently confirmed in the X-linked Alport syndrome mouse model [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis#H3785520947\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)&quot;, section on 'Heterozygous females with X-linked disease'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Autosomal recessive inheritance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autosomal recessive inheritance accounts for approximately 15 percent of patients with Alport syndrome [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/17\" class=\"abstract_t\">17</a>]. It arises from genetic defects in either the <em>COL4A3</em> or <em>COL4A4</em> genes. The <em>COL4A3</em> and <em>COL4A4</em> genes encode the alpha-3(IV) chain (which contains the Goodpasture antigen) and the alpha-4(IV) chain, respectively.</p><p>Females are as severely affected as males [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/14,23,24\" class=\"abstract_t\">14,23,24</a>], and the clinical manifestations in both sexes are virtually identical to those of classic X-linked Alport syndrome in males [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/23,25\" class=\"abstract_t\">23,25</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis#H3\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)&quot;, section on 'Clinical manifestations and course'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Autosomal dominant inheritance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based on studies utilizing next-generation sequencing, approximately 20 to 30 percent of patients with Alport syndrome have autosomal dominant disease, which arises from heterozygous mutations in the <em>COL4A3</em> or <em>COL4A4</em> genes [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/11,12,26-28\" class=\"abstract_t\">11,12,26-28</a>]. The clinical and pathologic features of this form are similar to those of X-linked disease, although deterioration of renal function tends to occur more slowly and ocular findings are unusual [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/29\" class=\"abstract_t\">29</a>].</p><p>It is unclear why some patients with heterozygous mutations in the <em>COL4A3</em> or <em>COL4A4</em> genes exhibit progressive renal disease (ie, autosomal dominant Alport syndrome), while others have nonprogressive or very slowly progressive renal disease (so-called &quot;thin basement membrane nephropathy&quot;) [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/27,28,30\" class=\"abstract_t\">27,28,30</a>]. Some evidence suggests that genetic factors other than mutations in these genes may affect underlying clinical features [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=thin-basement-membrane-nephropathy-benign-familial-hematuria\" class=\"medical medical_review\">&quot;Thin basement membrane nephropathy (benign familial hematuria)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Mechanism of glomerular injury</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The alpha-3, alpha-4, and alpha-5(IV) chains are highly expressed and co-distributed within the normal GBM [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/31\" class=\"abstract_t\">31</a>]. They form a type IV collagen network within the GBM that is distinct from that formed by alpha-1(IV) and alpha-2(IV) chains [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/2,32\" class=\"abstract_t\">2,32</a>]. Mutations affecting the alpha-3, alpha-4, and alpha-5(IV) chains impair their deposition into this collagen network, leading to secondary changes in GBM and resident glomerular cells that predispose to the development of glomerulosclerosis.</p><p>Several observations support this explanation of the pathophysiologic processes involved in Alport syndrome:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In most patients with alpha-5(IV) mutations, the alpha-3, alpha-4 chains, and alpha-5(IV) chains are all absent from the GBM [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/19\" class=\"abstract_t\">19</a>]. However, transcription of the alpha-3(IV) and alpha-4(IV) genes is not turned off in the renal cortex, suggesting that failure of incorporation of these chains is responsible for the lack of glomerular expression and not failure of synthesis [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/33\" class=\"abstract_t\">33</a>]. The GBM is characterized by the absence of the alpha-3, -4, and -5(IV) chains and by persistence of the fetal distribution of alpha-1 and alpha-2(IV) chains [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with autosomal recessive Alport syndrome, primary mutations in the alpha-3(IV) chain prevent the expression of the alpha-3, alpha-4, and alpha-5(IV) chains in GBM.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>This hypothesis is supported by observations in murine and dog models of Alport syndrome due to deletion of the alpha-3(IV) chain or a nonsense mutation of the alpha-5(IV) chain [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/34-38\" class=\"abstract_t\">34-38</a>]. As an example, in a murine model due to deletion of the alpha-3(IV) chain, abnormalities in the GBM included absence of alpha-4(IV) and alpha-5(IV) collagen chains, the overexpression of alpha-1(IV) and alpha-2(IV) chains and laminin alpha-5, and markedly elevated levels of fibronectin and perlecan (a heparan sulfate proteoglycan) in the basal laminae [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/35,37\" class=\"abstract_t\">35,37</a>].</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Monoclonal antibody probes have been used to determine the tissue distribution of the alpha-3, alpha-4, and alpha-5(IV) chains in normal tissues and tissues of Alport patients.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>These chains are normally located in Bowman's capsule and the basement membranes of the glomerulus, distal and collecting tubules, and several basement membranes of the cochlea and eye [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/39,40\" class=\"abstract_t\">39,40</a>]. Thus, an abnormality in any of these chains can impair the integrity of basement membranes in these sites leading to the various clinical findings of Alport syndrome.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In normal individuals the alpha-5(IV) chain is present in the basement membrane underlying the epidermis, as a component of alpha-5-5-6 networks. The alpha-3 and alpha-4(IV) chains are normally absent from the basement membrane.</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Skin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunohistochemical studies with a monoclonal antibody directed against the alpha-5(IV) chain demonstrated complete absence of alpha-5(IV) chain within epidermal basement membranes in most males with X-linked Alport syndrome, while female carriers had discontinuous staining (<a href=\"image.htm?imageKey=PEDS%2F72404\" class=\"graphic graphic_picture graphicRef72404 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/39\" class=\"abstract_t\">39</a>]. The latter observation is compatible with lyonization in female carriers, in whom it would be expected that one-half of their cells would express a normal alpha-5(IV) chain.</p><p>However, conventional fluorescence microscopy will detect alpha-5(IV) chain of the skin in approximately 20 percent of males with X-linked Alport syndrome and 30 to 40 percent of heterozygous females. Confocal laser scanning microscopy (CLSM) has demonstrated either a decrease in expression or an abnormal interrupted distribution of alpha-5(IV) compared with alpha-2(IV) chain staining in some but not all of these patients [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/41,42\" class=\"abstract_t\">41,42</a>]. Although this technique is currently primarily a research tool, these findings suggest that CLSM may play a future role in the diagnosis of Alport syndrome, as it appears to be a more sensitive diagnostic modality than conventional fluorescence microscopy.</p><p>All patients with autosomal recessive and autosomal dominant Alport syndrome have normal skin reactivity for alpha-5(IV) (<a href=\"image.htm?imageKey=PEDS%2F72404\" class=\"graphic graphic_picture graphicRef72404 \">picture 1</a>). Thus, the presence of epidermal basement membrane staining for alpha-5(IV) does not exclude a diagnosis of X-linked or autosomal Alport syndrome. However, the absence of alpha-5(IV) chain in a skin biopsy is diagnostic of X-linked Alport syndrome.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Kidney</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunostaining of renal biopsy specimens for type IV collagen is useful in the evaluation of patients with suspected Alport syndrome (<a href=\"image.htm?imageKey=PEDS%2F81373\" class=\"graphic graphic_figure graphicRef81373 \">figure 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>X-linked disease &mdash; As noted previously, males with X-linked Alport syndrome typically show complete absence of immunostaining for the alpha-3, alpha-4, and alpha-5(IV) chains in their kidneys, while heterozygous females exhibit patchy loss of staining in GBM and tubular basement membranes. (See <a href=\"#H7\" class=\"local\">'Mechanism of glomerular injury'</a> above.)</p><p/><p class=\"bulletIndent1\">As with skin staining for the alpha-5(IV) chain, approximately 20 percent of males with X-linked Alport syndrome have normal staining of renal basement membranes for the alpha-3, alpha-4, and alpha-5(IV) chains. Further quantitative analysis reveals lower amounts of the alpha-3, alpha-4, <span class=\"nowrap\">and/or</span> alpha-5(IV) chains in these cases compared with normals [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/43\" class=\"abstract_t\">43</a>]. Some of these patients have missense mutations of <em>COL4A5</em>, which may explain the detection of alpha IV chains with immunostaining, albeit with decreased intensity [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autosomal recessive disease &mdash; Patients with autosomal recessive Alport syndrome have abnormalities of renal type IV collagen expression that differ from those of patients with X-linked disease. These patients typically exhibit complete absence of staining for the alpha-3 and alpha-4(IV) chains. However, while their GBM show no staining for the alpha-5(IV) chain, there is staining of Bowman's capsules and distal tubular basement membranes for the alpha-5(IV) chain. This observation can be interpreted as failure of the alpha-5(IV) chain to be deposited in the GBM due to the absence of the alpha-3 and alpha-4(IV) chains, but the alpha-5(IV) chain, in conjunction with the alpha-6(IV) chain, is deposited in the basement membranes of the distal tubule, Bowman's capsules, and epidermis.</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Lens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anterior lenticonus, which is associated with thinning of the lens capsule, the basement membrane that surrounds the lens, occurs in 20 to 30 percent of males with X-linked Alport syndrome. If present, anterior lenticonus is pathognomonic for Alport syndrome. The lens capsule normally contains alpha-3, alpha-4, and alpha-5(IV) chains. In some patients with anterior lenticonus, these chains are absent from the lens capsule [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Cochlea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hearing loss in Alport syndrome likely reflects abnormal function of cochlear basement membranes due to the absence of the alpha-3-4-5 type IV collagen network [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/46\" class=\"abstract_t\">46</a>]. The precise mechanism for hearing loss in Alport syndrome remains under investigation.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Other pathologic findings</span></p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Leiomyomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leiomyomas are benign tumors characterized by visceral smooth muscle overgrowth within the respiratory, gastrointestinal, and female reproductive tracts. Rarely, X-linked Alport syndrome is associated with leiomyomas. Affected patients carry deletions that involve <em>COL4A5</em> and extend into the second intron of the adjacent COL4A6 gene [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/47\" class=\"abstract_t\">47</a>]. Of note, defects in the alpha-6 chain gene alone do not appear to cause Alport syndrome [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>The pathogenetic relationship between deletions of the 5' end of the <em>COL4A6</em> gene and the formation of leiomyomas is not understood. One hypothesis suggests that deletions that encompass both the <em>COL4A5</em> and <em>COL4A6</em> genes cause misregulation of neighboring genes, which contribute to smooth muscle overgrowth [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">RENAL PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologic changes in Alport kidneys increase in severity with age. The changes on light microscopy are nonspecific and include focal increases in glomerular cellularity progressing to glomerulosclerosis and interstitial fibrosis-tubular atrophy over time, and an interstitial infiltrate containing lipid-laden foam cells of uncertain origin.</p><p>The earliest ultrastructural lesion is thinning of the GBM [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/2,48\" class=\"abstract_t\">2,48</a>]. With time, there is development of longitudinal splitting of the lamina densa of the GBM producing a laminated appearance that is diagnostic of Alport syndrome (<a href=\"image.htm?imageKey=NEPH%2F68942%7ENEPH%2F79434\" class=\"graphic graphic_picture graphicRef68942 graphicRef79434 \">picture 2A-B</a>). In males with X-linked Alport syndrome, the proportion of GBM showing splitting increases from approximately 30 percent by age 10 to more than 90 percent by age 30 [<a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/48\" class=\"abstract_t\">48</a>]. A similar progression likely occurs in patients with autosomal recessive Alport syndrome. Females with X-linked Alport syndrome, and males and females with autosomal dominant Alport syndrome, may have thin GBM or a mix of thin and lamellated GBM. (See <a href=\"topic.htm?path=thin-basement-membrane-nephropathy-benign-familial-hematuria\" class=\"medical medical_review\">&quot;Thin basement membrane nephropathy (benign familial hematuria)&quot;</a>.)</p><p>Renal biopsy of affected individuals at a young age may manifest only non-specific light microscopic changes and no definitive electron microscopic findings. However, results of immunostaining for type IV collagen alpha chains is frequently diagnostic even in the absence of specific ultrastructural changes. In some patients, less invasive skin biopsy with appropriate immunohistochemical analysis may be the preferred diagnostic study. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis#H10\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)&quot;, section on 'Diagnosis'</a> and <a href=\"#H9\" class=\"local\">'Skin'</a> above.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alport syndrome (hereditary nephritis) is a progressive inherited form of glomerular disease that is often associated with neural hearing loss and ocular abnormalities. Alport syndrome is a primary basement membrane disorder arising from mutations in genes encoding several members of the type IV collagen protein family.</p><p>Alport syndrome is a genetically heterogeneous disease with X-linked, autosomal recessive, and autosomal dominant variants. (See <a href=\"#H3\" class=\"local\">'Genetics'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>X-linked variant accounts for the majority of affected patients. It arises from mutations in the COL4A5 gene on the X chromosome, which encodes alpha-5(IV) chains. (See <a href=\"#H4\" class=\"local\">'X-linked inheritance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autosomal recessive variant accounts for approximately 15 percent of patients with Alport syndrome. It arises from genetic defects in either the <em>COL4A3</em> or <em>COL4A4</em> genes, which encodes the alpha-3 and alpha-4(IV) chains, respectively. The clinical manifestations of affected patients regardless of gender are the same as male patients with X-linked Alport syndrome. (See <a href=\"#H5\" class=\"local\">'Autosomal recessive inheritance'</a> above and <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autosomal dominant disease appears to account for 20 to 30 percent of patients with Alport syndrome, based on results of next generation sequencing studies. It arises from heterozygous mutations in the <em>COL4A3</em> or <em>COL4A4</em> genes. The clinical and pathologic features of this variant of Alport syndrome are similar to those of X-linked disease, although deterioration of renal function tends to occur more slowly, and sensorineural hearing loss and ocular abnormalities are unusual. (See <a href=\"#H6\" class=\"local\">'Autosomal dominant inheritance'</a> above.)</p><p/><p>The alpha-3, alpha-4, and alpha-5(IV) chains are normally located in Bowman's capsule, and the basement membranes of the glomerulus, distal and collecting tubules, cochlea, and eye. Thus, an abnormality in any of these chains can impair the integrity of basement membranes in these sites, leading to the various clinical findings of Alport syndrome. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis#H3\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)&quot;, section on 'Clinical manifestations and course'</a> and <a href=\"#H7\" class=\"local\">'Mechanism of glomerular injury'</a> above and <a href=\"#H8\" class=\"local\">'Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution'</a> above.)</p><p>In patients with Alport syndrome, renal histologic changes progress with age. The earliest finding is thinning of the GBM. With increasing age, longitudinal splitting of the lamina densa of the GBM produces a laminated appearance that is diagnostic of Alport syndrome and is present in 90 percent of male patients by 30 years of age (<a href=\"image.htm?imageKey=NEPH%2F68942%7ENEPH%2F79434\" class=\"graphic graphic_picture graphicRef68942 graphicRef79434 \">picture 2A-B</a>). (See <a href=\"#H15\" class=\"local\">'Renal pathology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/1\" class=\"nounderline abstract_t\">Gr&uuml;nfeld JP. The clinical spectrum of hereditary nephritis. Kidney Int 1985; 27:83.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/2\" class=\"nounderline abstract_t\">Kashtan CE, Michael AF. Alport syndrome. Kidney Int 1996; 50:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/3\" class=\"nounderline abstract_t\">Kashtan CE. Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr 2004; 16:177.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/4\" class=\"nounderline abstract_t\">Massella L, Onetti Muda A, Faraggiana T, et al. Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease. Kidney Int 2003; 64:1787.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/5\" class=\"nounderline abstract_t\">Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/6\" class=\"nounderline abstract_t\">Persson U, Hertz JM, Wieslander J, Segelmark M. Alport syndrome in southern Sweden. Clin Nephrol 2005; 64:85.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/7\" class=\"nounderline abstract_t\">Heidet L, Gubler MC. The renal lesions of Alport syndrome. J Am Soc Nephrol 2009; 20:1210.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/8\" class=\"nounderline abstract_t\">McCoy RC, Johnson HK, Stone WJ, Wilson CB. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 1982; 21:642.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/9\" class=\"nounderline abstract_t\">Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15:2514.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/10\" class=\"nounderline abstract_t\">Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992; 42:179.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/11\" class=\"nounderline abstract_t\">Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 2014; 86:252.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/12\" class=\"nounderline abstract_t\">Morini&egrave;re V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 2014; 25:2740.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/13\" class=\"nounderline abstract_t\">Heiskari N, Zhang X, Zhou J, et al. Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol 1996; 7:702.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/14\" class=\"nounderline abstract_t\">Tryggvason K, Zhou J, Hostikka SL, Shows TB. Molecular genetics of Alport syndrome. Kidney Int 1993; 43:38.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/15\" class=\"nounderline abstract_t\">Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/16\" class=\"nounderline abstract_t\">Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/17\" class=\"nounderline abstract_t\">Torra R, Taz&oacute;n-Vega B, Ars E, Ballar&iacute;n J. Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure. Nephrol Dial Transplant 2004; 19:2429.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/18\" class=\"nounderline abstract_t\">Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248:1224.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/19\" class=\"nounderline abstract_t\">Antignac C, Knebelmann B, Drouot L, et al. Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression. J Clin Invest 1994; 93:1195.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/20\" class=\"nounderline abstract_t\">Rheault MN, Kren SM, Thielen BK, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 2004; 15:1466.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/21\" class=\"nounderline abstract_t\">Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a &quot;European Community Alport Syndrome Concerted Action&quot; study. J Am Soc Nephrol 2003; 14:2603.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/22\" class=\"nounderline abstract_t\">Rheault MN, Kren SM, Hartich LA, et al. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 2010; 25:764.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/23\" class=\"nounderline abstract_t\">Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994; 8:77.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/24\" class=\"nounderline abstract_t\">Longo I, Scala E, Mari F, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant 2006; 21:665.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/25\" class=\"nounderline abstract_t\">Dagher H, Buzza M, Colville D, et al. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 2001; 38:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/26\" class=\"nounderline abstract_t\">van der Loop FT, Heidet L, Timmer ED, et al. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 2000; 58:1870.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/27\" class=\"nounderline abstract_t\">Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 2002; 61:1947.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/28\" class=\"nounderline abstract_t\">Pescucci C, Mari F, Longo I, et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 2004; 65:1598.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/29\" class=\"nounderline abstract_t\">Pochet JM, Bobrie G, Landais P, et al. Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant 1989; 4:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/30\" class=\"nounderline abstract_t\">Gross O, Netzer KO, Lambrecht R, et al. Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. Nephrol Dial Transplant 2003; 18:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/31\" class=\"nounderline abstract_t\">Kim Y, Kleppel MM, Butkowski R, et al. Differential expression of basement membrane collagen chains in diabetic nephropathy. Am J Pathol 1991; 138:413.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/32\" class=\"nounderline abstract_t\">Kobayashi T, Uchiyama M. Characterization of assembly of recombinant type IV collagen alpha3, alpha4, and alpha5 chains in transfected cell strains. Kidney Int 2003; 64:1986.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/33\" class=\"nounderline abstract_t\">Nakanishi K, Yoskikawa N, Iijima K, Nakamura H. Expression of type IV collagen alpha 3 and alpha 4 chain mRNA in X-linked Alport syndrome. J Am Soc Nephrol 1996; 7:938.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/34\" class=\"nounderline abstract_t\">Kalluri R, Shield CF, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997; 99:2470.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/35\" class=\"nounderline abstract_t\">Miner JH, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol 1996; 135:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/36\" class=\"nounderline abstract_t\">Harvey SJ, Zheng K, Sado Y, et al. Role of distinct type IV collagen networks in glomerular development and function. Kidney Int 1998; 54:1857.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/37\" class=\"nounderline abstract_t\">Abrahamson DR, Isom K, Roach E, et al. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects. J Am Soc Nephrol 2007; 18:2465.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/38\" class=\"nounderline abstract_t\">Kashtan CE. Animal models of Alport syndrome. Nephrol Dial Transplant 2002; 17:1359.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/39\" class=\"nounderline abstract_t\">Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/40\" class=\"nounderline abstract_t\">Zehnder AF, Adams JC, Santi PA, et al. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg 2005; 131:1007.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/41\" class=\"nounderline abstract_t\">Muda AO, Massella L, Giannakakis K, et al. Confocal microscopy of the skin in the diagnosis of X-linked Alport syndrome. J Invest Dermatol 2003; 121:208.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/42\" class=\"nounderline abstract_t\">Patey-Mariaud de Serre N, Garfa M, Bessi&eacute;res B, et al. Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients. Kidney Int 2007; 72:512.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/43\" class=\"nounderline abstract_t\">Su J, Liu ZH, Zeng CH, et al. Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy. Nephrol Dial Transplant 2006; 21:1838.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/44\" class=\"nounderline abstract_t\">Naito I, Kawai S, Nomura S, et al. Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome. Japanese Alport Network. Kidney Int 1996; 50:304.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/45\" class=\"nounderline abstract_t\">Cheong HI, Kashtan CE, Kim Y, et al. Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome. Lab Invest 1994; 70:553.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/46\" class=\"nounderline abstract_t\">Merchant SN, Burgess BJ, Adams JC, et al. Temporal bone histopathology in alport syndrome. Laryngoscope 2004; 114:1609.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/47\" class=\"nounderline abstract_t\">Dahan K, Heidet L, Zhou J, et al. Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. Kidney Int 1995; 48:1900.</a></li><li><a href=\"https://www.uptodate.com/contents/genetics-pathogenesis-and-pathology-of-alport-syndrome-hereditary-nephritis/abstract/48\" class=\"nounderline abstract_t\">Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6086 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H16\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Genetics</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- X-linked inheritance</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Autosomal recessive inheritance</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Autosomal dominant inheritance</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Mechanism of glomerular injury</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Skin</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Kidney</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Lens</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Cochlea</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">Other pathologic findings</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">- Leiomyomas</a></li></ul></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">RENAL PATHOLOGY</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6086|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/81373\" class=\"graphic graphic_figure\">- Immunohistol kidney Alport</a></li></ul></li><li><div id=\"PEDS/6086|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/72404\" class=\"graphic graphic_picture\">- Immunohistology skin Alport</a></li><li><a href=\"image.htm?imageKey=NEPH/68942\" class=\"graphic graphic_picture\">- Hereditary nephritis EM</a></li><li><a href=\"image.htm?imageKey=NEPH/79434\" class=\"graphic graphic_picture\">- Hereditary nephritis IF</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-alport-syndrome-hereditary-nephritis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thin-basement-membrane-nephropathy-benign-familial-hematuria\" class=\"medical medical_review\">Thin basement membrane nephropathy (benign familial hematuria)</a></li></ul></div></div>","javascript":null}